ZENICOR MEDICAL SYSTEMS AB
NNGM:ZENI0.89
SEK
+0.01
(+0.56%)
ISIN
SE0006343984
Return %
Stock
S&P 500
1Y
-35.97
14.20
3Y
-71.66
81.12
5Y
-96.83
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Mats Håkan Palerius
- Full Time Employees
- 19
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Stockholm Sweden
- IPO Date
- Nov 18, 2014
- Website
- zenicor.se
- Similar Companies
- Business
- Zenicor Medical Systems AB is a medical technology company that develops and commercializes advanced diagnostic systems, software, and clinical care pathways for the early detection of cardiac arrhythmias and stroke prevention. Founded in 2003 and headquartered in Stockholm, Sweden, the company specializes in digital cardiac monitoring solutions designed to replace traditional diagnostic methods and streamline arrhythmia investigations across primary, secondary, and specialized healthcare settings. Zenicor Medical Systems operates within the healthcare and medical device sector, delivering solutions to hospitals, cardiology clinics, primary care centers, stroke units, and clinical research institutions across Europe, with primary market presence in Sweden, Norway, Denmark, Finland, Germany, the United Kingdom, Austria, and Switzerland. The company’s core offering encompasses the Zenicor Solution, an integrated hardware, software, and service ecosystem that includes: Zenicor One, a handheld, patient-activated thumb-ECG device featuring integrated 4G and 5G cellular connectivity for prolonged intermittent cardiac rhythm recording; Zenicor Flex, a continuous monitoring solution utilizing wearable ECG patches or standard electrode configurations for extended multi-day rhythm analysis; Zenicor View, a centralized, cloud-based clinical software application and database that allows healthcare providers to securely view, interpret, and manage diagnostic ECG recordings; and Zenicor Direct, a comprehensive service package providing healthcare facilities with remote ECG interpretation support, administrative assistance, and end-to-end device logistics management. In recent developments, Zenicor Medical Systems has advanced its regulatory status, clinical integration, and international commercial expansion. The company secured European Union Medical Device Regulation (EU MDR) Class IIa certification for its complete Zenicor-ECG hardware, software, and service platform, establishing regulatory compliance across European markets. Zenicor has integrated advanced artificial intelligence algorithms into its diagnostic analysis platform, supported by grant funding from Sweden's innovation agency, Vinnova, to enhance automated arrhythmia detection accuracy. Commercially, the company expanded its public healthcare footprint by securing a public procurement contract with the Helsinki University Hospital (HUS) health authority in Finland and achieving primary care adoption approvals and supply agreements within the National Health Service (NHS) in the United Kingdom, including regional trusts in West Yorkshire and Northamptonshire. Additionally, Zenicor's diagnostic technology reached major operational milestones in large-scale cardiac screening trials, including the completion of data collection and participant screening in the STROKESTOP and SAFER clinical studies, while the company executed a rights issue to finance continued international expansion and SaaS platform scaling.